Skip to main content

National Institutes of Health

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development

Upcoming

Decision brief

Who can apply
GovernmentNonprofitsSmall BusinessHigher EducationOtherNonprofits (preferred)
Award amount
Not specified
Deadline
Jun 16, 2027
Geography
National
Application notesHigh effort
  • Federal application
  • 4 awards expected — competitive
  • Cooperative agreement — ongoing federal oversight

Next step

Apply at Grants.gov

View Source

Focus areas

About this grant

The NIH Blueprint for Neuroscience Research is interested in continuing to support the B lue P rint N eurotherapeutics Network for S mall M olecules (BPN-SM)- a program designed to help investigators advance promising small-molecule therapeutics toward clinical testing. The BPN-SM program supports drug discovery and development activities in investigators’ own laboratories while also providing access to NIH-supported subject matter experts and contract research organizations (CROs) with capabilities in medicinal chemistry, pharmacokinetics, toxicology, formulation development, GMP synthesis, and Phase I clinical testing. By integrating NIH resources with industry-standard expertise, BPN-SM advances investigator-initiated drug discovery while enabling investigators to retain and strengthen their intellectual property while gaining hands-on experience in translational drug development. The overarching goal of the program is to reduce the risk of scientific and therapy development sufficiently to enable external partners to take on late-stage development and ultimately bring new therapies to patients. In addition, this BPN program is specifically focused on small molecules and excludes biologics, because development, regulatory, and manufacturing considerations for each class of therapeutics differ substantially from each other. It will use a phased cooperative agreement mechanism which will enable the program to support innovative but higher-risk projects, with decisions of continued support being contingent on demonstrated feasibility of yearly milestones. A cooperative agreement framework is proposed because several key aspects of the program will involve collaborative activities between the investigators and NIH program staff, with substantial involvement beyond the normal scope of grant stewardship. The project principal investigator(s) and NIH program staff will work jointly with NIH-supported subject matter experts to coordinate and participate in all scientific and technical management aspects of the project. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop competitive projects and establish the cross-disciplinary collaborations necessary for success.

Additional details

CFDA / ALN Number
93.853
Program Title
Extramural Research Programs in the Neurosciences and Neurological Disorders
Expected Awards
4
Funding Instrument
Cooperative Agreement
Source
Grants.gov · View original listing

Similar grants